Company profile for ImmunAbs

NEW Drugs in Dev: 1
PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ImmunAbs has various antibody screening and engineering technologies such as phage display, single B cell cloning, and bispecific antibody development. Phage display is one of the main screening tools in this field. It is a method that displays various antibodies on bacteriophage surface and screens for high affinity antibodies from the bacteriophage library. Single B cell cloning involves isolation of antibody genes after scr...
ImmunAbs has various antibody screening and engineering technologies such as phage display, single B cell cloning, and bispecific antibody development. Phage display is one of the main screening tools in this field. It is a method that displays various antibodies on bacteriophage surface and screens for high affinity antibodies from the bacteriophage library. Single B cell cloning involves isolation of antibody genes after screening single B cells that express high affinity antibodies against a target antigen. Members of ImmunAbs have experience in screening antibodies and proceeding them to phase II clinical trials using such technologies.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
South Korea
Address
Address
Gangnam-gu Second Floor, 427 Teheran-ro Seoul South Korea
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20250602209751/en/ImmunAbs-Announces-FDA-Phase-2-IND-Approval-of-IM-101-a-Novel-Complement-C5-Inhibitor-for-Treatment-of-Myasthenia-Gravis

BUSINESSWIRE
02 Jun 2025

https://www.prnewswire.com/news-releases/immunabs-announces-conclusion-of-phase-1-clinical-trial-revealing-positive-topline-results-302084998.html

PR NEWSWIRE
11 Mar 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty